Literature DB >> 28295944

Paracentral acute middle maculopathy as a finding in patients with severe vision loss following phacoemulsification cataract surgery.

Katarina Creese1,2, Daini Ong1,2, Sukhpal S Sandhu1,2, David Ware3, C Alex Harper1,2, Salmaan H Al-Qureshi1,2, Sanjeewa S Wickremasinghe1,2.   

Abstract

IMPORTANCE: Paracentral acute middle maculopathy (PAMM) diagnosed by spectral domain optical coherence tomography (SD-OCT) in patients with poor visual outcome post cataract surgery.
BACKGROUND: Case series of severe vision loss due to PAMM after cataract surgery.
DESIGN: Retrospective case series. PARTICIPANTS: Cases from five surgical centres in Victoria, Australia.
METHODS: Retrospective analysis of cases with unexplained 'patch-off' vision loss post cataract surgery. All patients in our cohort had PAMM and presumed diagnosis of central or transient retinal artery occlusion. MAIN OUTCOME MEASURES: A review of the patient histories focusing on pre-operative ocular and systemic vascular risk factors, anaesthetic and operative factors.
RESULTS: Ten cases were included. All patients had 6/72 Snellen visual acuity or worse noted on day one post surgery. Three patients had features of central retinal artery occlusion consisting of retinal pallor with a 'cherry red' macula but absent relative afferent pupillary defect. Seven had no features of retinal pallor or attenuation of retinal arterioles. On SD-OCT, all eyes had evident PAMM. Six patients had a history of cardiovascular disease or blood dyscrasia. CONCLUSIONS AND RELEVANCE: PAMM should be considered in patients with 'patch off' visual loss and absence of other fundal signs. We hypothesise that spasm or transient occlusion of central retinal artery leads to arterial hypoperfusion with subsequent ischaemia or infarction of the retina. Underlying arterial disease may have led to pre-existing hypoperfusion that may have been further compromised by raised intraocular pressure during the procedure itself or via raised orbital pressure from the anaesthesia.
© 2017 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  cataract surgery; paracentral acute middle maculopathy; retinal artery occlusion

Mesh:

Year:  2017        PMID: 28295944     DOI: 10.1111/ceo.12945

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  6 in total

Review 1.  Paracentral acute middle maculopathy-review of the literature.

Authors:  Nuno Moura-Coelho; Teresa Gaspar; Joana Tavares Ferreira; Marco Dutra-Medeiros; João Paulo Cunha
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-07-13       Impact factor: 3.117

2.  [Phacoemulsification cataract surgery with different cumulative energy composite parameters in patients with type 2 diabetes mellitus:therapeutic effect and complications].

Authors:  Jianwei Zhai; Wei Su; Zuoyi Tang; Lanfen Lu; Xiaotang Huang; Liudan Wei
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-04-30

3.  A unique case of Paracentral Acute Middle Maculopathy with associated cystoid macular oedema post uncomplicated pterygium surgery.

Authors:  Waseem Henein; Ario Wilson-Pogmore; Fraser Imrie
Journal:  Am J Ophthalmol Case Rep       Date:  2020-09-23

4.  A case of paracentral acute middle maculopathy after small incision lenticule extraction surgery.

Authors:  Li-Hui Meng; Xin-Yu Zhao; Wei-Hong Yu; You-Xin Chen
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

5.  Transient vision loss associated with paracentral acute middle maculopathy detected on multi-modal imaging.

Authors:  Jesse D Sengillo; Lily Zhang; Jayanth Sridhar; Harry W Flynn; Stephen G Schwartz
Journal:  Am J Ophthalmol Case Rep       Date:  2021-08-26

6.  Paracentral acute middle maculopathy after uneventful ocular surgery with local anaesthetic blocks.

Authors:  Carolina Bernal-Morales; Daniel Velazquez-Villoria; Juan Manuel Cubero-Parra; Pearse A Keane; Dawn A Sim; Alfredo Adán; Adnan Tufail; Javier Zarranz-Ventura
Journal:  Eye (Lond)       Date:  2021-03-08       Impact factor: 3.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.